EORTC Genito Urinary Cancers Group Virtual Meeting
October 6, 2020
Virtual Event
The EORTC Genito Urinary Cancers Group Virtual Meeting will be held from 13:00 to 15:30 CET.
Programme
13:00-13:20 Introduction
Welcome and introduction of the attendees
COVID-19 impact
Status of the group, Steps to improve
Speaker: A.Bex
Prostate Cancer: Update of running studies:
13:20-13:35 1333-GUCG (PEACE III)
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.
Speaker: S.Gillessen/B.Tombal
13:35-13:45 1532-GUCG (ODM-201)
A Phase 2 Randomized Open-Label Safety and Efficacy Study of Oral ODM-201 vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer.
Speaker: B.Tombal
13:45-14:00 1414-ROG-GUCG (DEGARELIX)
Phase III randomized trial comparing irradiation plus long term adjuvant androgen suppression with LHRH antagonist versus LHRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG.
Speaker: D.Böhmer
14:00-14:15 Update on non-EORTC led studies:
1201-GUCG (PEACE I)
A prospective randomised phase III study of androgen deprivation therapy (+/- docetaxel) with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.
1545-GUCG (ENZARAD)
Randomised phase 3 trial of Enzalutamide in Androgen Deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer.
30072-GUCG (SORCE)
A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse
Renal cell carcinoma projects
14:15-14:20 QoL GUCG collaboration
Speaker: A.Bex
14:20-14:30 30073 SURTIME additional analysis
Speaker: A.Bex
EORTC SPECTA projects
14:30-14:45 IMMUcan and Arcagen
Speaker: A.Bex
14:45-15:00 E2-RADIatE
Speaker: E. Peeters
Germ Cell Cancer
15:00-15:15 1407-GUCG (TIGER)
A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by High-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumours.
Speaker: T.Powles
15:15-15:20 IGCCCG2. REVIEW OF IGCCCG CLASSIFICATION: Update
Speaker: A.Neven
15:20-15:30 Q&A: Closure of the meeting & announcement of the next GUCG meeting
Speaker: A.Bex
Next events
Cancer Medicines Forum workshop
April 5
Amsterdam, NL (Hybrid Event)
Spring Roundtable – Encontros da Primavera
April 10 - April 13
Evora, Portugal
EORTC Breast Cancer Group Spring Meeting
April 12
Virtual Event
CDDF Workshop on Clinical Research in Central and Eastern Europe
April 15 - April 16
Karkow (Hybrid)
EORTC Imaging Group Spring Meeting
April 19
Brussels, Belgium (hybrid)